However, head-to-head studies (anti-IL17 vs. anti-TNFα) for patients with both psoriasis and PsA showed that ixekizumab was superior to adalimumab in the achievement of simultaneous improvement of joint and skin disease (combined ACR50 and PASI100) [49]. The gene discussed is IL17A; the disease is psoriasis.